Abstract
Background: Stroke remains the second commonest cause of death and leading cause of adult disability worldwide. Ischemic events account for nearly 85% of all strokes, and hemorrhages account for nearly 15%. Stroke intervention and recovery have been identified as the important factors in the functional outcome of patients with completed stroke. However, the only FDA approved treatment for ischemic strokes is tissue plasminogen activator, and no effective targeted therapy for hemorrhagic stroke exists yet.
Methods: The goal of this work is to review the brain drug delivery systems (BDDS) used for stroke intervention and recovery. Results: Many novel BDDS have been developed for the use of stroke intervention and recovery, including nanoparticles, hydrogels, fibers, liposomes, and so on, which could improve the permeability of blood-brainbarrier (BBB), short half-life, stability in vivo, and reduce adverse effects of drugs. Conclusion: Combined with new drug targets in the treatment of stroke, BDDS will provide more effective therapeutics for stroke intervention and recovery.Keywords: Brain drug delivery, ischemic stroke, intracerebral hemorrhage, stroke intervention, stroke recovery.
Current Pharmaceutical Design
Title:Brain Drug Delivery Systems for the Stroke Intervention and Recovery
Volume: 23 Issue: 15
Author(s): Tiantian Luo, Ju Wang, Shilei Hao*, Tingwang Guo, Peng Ren, Zhongjun Cheng, Feiyan Gao, Yuhua Gong and Bochu Wang*
Affiliation:
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400030,China
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400030,China
Keywords: Brain drug delivery, ischemic stroke, intracerebral hemorrhage, stroke intervention, stroke recovery.
Abstract: Background: Stroke remains the second commonest cause of death and leading cause of adult disability worldwide. Ischemic events account for nearly 85% of all strokes, and hemorrhages account for nearly 15%. Stroke intervention and recovery have been identified as the important factors in the functional outcome of patients with completed stroke. However, the only FDA approved treatment for ischemic strokes is tissue plasminogen activator, and no effective targeted therapy for hemorrhagic stroke exists yet.
Methods: The goal of this work is to review the brain drug delivery systems (BDDS) used for stroke intervention and recovery. Results: Many novel BDDS have been developed for the use of stroke intervention and recovery, including nanoparticles, hydrogels, fibers, liposomes, and so on, which could improve the permeability of blood-brainbarrier (BBB), short half-life, stability in vivo, and reduce adverse effects of drugs. Conclusion: Combined with new drug targets in the treatment of stroke, BDDS will provide more effective therapeutics for stroke intervention and recovery.Export Options
About this article
Cite this article as:
Luo Tiantian, Wang Ju, Hao Shilei*, Guo Tingwang, Ren Peng, Cheng Zhongjun, Gao Feiyan, Gong Yuhua and Wang Bochu*, Brain Drug Delivery Systems for the Stroke Intervention and Recovery, Current Pharmaceutical Design 2017; 23 (15) . https://dx.doi.org/10.2174/1381612822666161025155058
DOI https://dx.doi.org/10.2174/1381612822666161025155058 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology
Current Pharmaceutical Design The Stroke-Induced Blood-Brain Barrier Disruption: Current Progress of Inspection Technique, Mechanism, and Therapeutic Target
Current Neuropharmacology Current Understanding of In-stent Restenosis and the Potential Benefit of Drug Eluting Stents
Current Drug Targets - Cardiovascular & Hematological Disorders Nimodipine Loaded PLGA Nanoparticles: Formulation Optimization Using Factorial Design,Characterization and In Vitro Evaluation
Current Drug Delivery <i>Uncaria rhynchophylla</i> and its Major Constituents on Central Nervous System: A Review on Their Pharmacological Actions
Current Vascular Pharmacology The Clinical Usefulness of Nuclear Medicine Techniques in the Diagnosis of Vascular Graft Infections
Current Molecular Imaging (Discontinued) Genetic Determinants of Cerebral Arterial Adaptation to Flow-loading
Current Neurovascular Research Immune-Mediated Mechanisms in Atherosclerosis: Prevention and Treatment of Clinical Manifestations
Current Pharmaceutical Design Pathogenic and Therapeutic Significance of Angiotensin II Type I Receptor in Abdominal Aortic Aneurysms
Current Drug Targets The Location of Vascular Flap is Related with Daily Activity Patterns in Non-traumatic Acute Aortic Syndrome in a Chinese Population
Current Signal Transduction Therapy Indicators of Cardiovascular Risk in Metabolic Syndrome: Long Term Follow-up in Italian Patients
Current Vascular Pharmacology CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design A Cerebrovascular Image Segmentation Method Based on Geometrical Feature Point Clustering and Local Threshold
Current Medical Imaging Structural Development, Haematological Immunological and Pharmacological Effects of Quinolones
Recent Patents on Anti-Infective Drug Discovery Intraventricular Recombinant Tissue Plasminogen Activator in Treatment of Aneurysmal Intraventricular Hemorrhage: A Meta-Analysis
Current Drug Targets Antithrombotic Treatment Management in Patients with Intracerebral Hemorrhage: Reversal and Restart
Current Pharmaceutical Design MicroRNAs as Biomarkers for Birth Defects
MicroRNA Kawasaki Disease and Its Treatment – An Update
Current Rheumatology Reviews Preface
Recent Patents on Medical Imaging Infection-Associated Biomarkers of Inflammation in Atherosclerosis
Current Pharmaceutical Design